Trump speeds up review and funding for psychedelic medicines, including ibogaine
TL;DR
President Trump directed HHS to accelerate reviews and funding for psychedelic drugs, including ibogaine, as the FDA plans fast-track vouchers to shorten approval times; the move seeks medical uses for conditions like PTSD and depression but faces concerns over safety and the drugs’ Schedule I status.
- Trump signs order to hasten review of psychedelics PBS
- Trump signs order fast tracking review of psychedelics for mental health disorders NPR
- Trump Signs Executive Order to Loosen Restrictions on Psychedelic Drugs The New York Times
- Trump signs order to speed review of psychedelics, including the controversial drug ibogaine AP News
- Trump announces reforms to accelerate access to psychedelic drug treatments The Guardian
Want the full story? Read the original reporting
Read on PBS